Early Detection of Triple Negative Breast Cancer Relapse

NANot yet recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 15, 2026

Study Completion Date

December 15, 2028

Conditions
Triple Negative Breast Cancer
Interventions
DIAGNOSTIC_TEST

ctDNA monitoring

For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.

DIAGNOSTIC_TEST

68Ga-FAPI-46-PET-CT

). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.

Trial Locations (13)

13009

Institut Paoli-Calmettes, Marseille

30900

CHU Nîmes, Nîmes

31059

ONCOPOLE Claudius Regaud, Toulouse

33000

Institut Bergonié, Bordeaux

34298

Institut du cancer de Montpellier, Montpellier

35000

Centre Eugène Marquis, Rennes

54519

Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy

63011

Centre Jean Perrin, Clermont-Ferrand

69008

Centre Leon Bérard, Lyon

75010

Hôpital Saint-Louis, Paris

75020

Hôpital Tenon, Paris

84918

Sainte-Catherine Institut du Caner Avignon-Provence, Avignon

92340

Institut Curie, Saint-Cloud

All Listed Sponsors
collaborator

National Research Agency, France

OTHER

collaborator

Roche Pharma AG

INDUSTRY

lead

Institut Curie

OTHER

NCT06225505 - Early Detection of Triple Negative Breast Cancer Relapse | Biotech Hunter | Biotech Hunter